(2R)-2-hydroxy-3-(2-hydroxyphenyl)propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (2R)-2-hydroxy-3-(2-hydroxyphenyl)propanoic acid
• 化学式: C₉H₁₀O₄
• 分子量: 182.17
• InChiKey: HXQBZGMVGIDZAJ-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• [EN] 2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS D'ACIDE 2-((5-(PHÉNYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHÉNYL)PROPANOÏQUE ET COMPOSÉS APPARENTÉS SERVANT D'INHIBITEURS D'ENZYME MCL-1 POUR LE TRAITEMENT DU CANCER
  申请人：PRELUDE THERAPEUTICS INC

  公开号：WO2020123994A1

  公开（公告）日：2020-06-18

  A compound of formula I (the variables are defined in the claims) or a pharmaceutically acceptable salt or solvate thereof, as an MCL-1 enzyme inhibitor for treating colon cancer, breast cancer, small-cell lung cancer, non-small- cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer. The present description discloses the synthesis of exemplary compounds as well as biological assays thereof (e.g. pages 55 to 114; paragraphs [00216] to [00304]; examples 1 to 33; tables A and 2). An exemplary compound is e.g. (2R)-2-[(5Ra)-5-3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl) ethoxy]phenyl}-6-(4-fluorophenyl) py rrolo[2, l-f][l, 2, 4]triazin-4-yl]am ino}-3-(2-[2-(2-methoxy phenyl) py rim idin-4-yl]methoxy} phenyl) propanoic acid (example 13) with e.g. 0.7 nM BIM_Ki in an cell free MCL-1 Bim affinity assay.

  化合物I的化学式（变量在权利要求中定义）或其药学上可接受的盐或溶剂，作为MCL-1酶抑制剂，用于治疗结肠癌、乳腺癌、小细胞肺癌、非小细胞肺癌、膀胱癌、卵巢癌、前列腺癌、慢性淋巴细胞白血病、淋巴瘤、骨髓瘤、急性髓系白血病或胰腺癌。本说明书披露了示例化合物的合成以及生物测定（例如第55至114页；段落[00216]至[00304]；示例1至33；表A和2）。例如，一种示例化合物是(2R)-2-[(5Ra)-5-3-氯-2-甲基-4-[2-(4-甲基哌嗪-1-基)乙氧基]苯基}-6-(4-氟苯基)吡咯[2，1-f][1,2,4]三嗪-4-基]氨基}-3-(2-[2-(2-甲氧基苯基)嘧啶-4-基]甲氧基}苯基)丙酸（示例13），在无细胞MCL-1 Bim亲和力测定中，其BIM_Ki为0.7 nM。
• THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20150175623A1

  公开（公告）日：2015-06-25

  Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 12 , X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如说明中所述。含有该化合物的药物可用于治疗涉及凋亡缺陷的病理学，如癌症、自身免疫性疾病和免疫系统疾病。
• Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
  申请人：LES LABORATOIRES SERVIER

  公开号：US10278972B2

  公开（公告）日：2019-05-07

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)化合物： 其中 R1、R2、R3、R4、R5、R6、R7、R12、X、A 和 n 如说明中所定义。 含有相同成分的药物产品，可用于治疗涉及细胞凋亡缺陷的病症，如癌症、自身免疫性疾病和免疫系统疾病。
• New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
  申请人：Les Laboratoires Servier

  公开号：EP2886545B1

  公开（公告）日：2016-06-29